POPULARITY
16 episodes with ny may
17 episodes with ny may
5 episodes with ny may
20 episodes with ny may
8 episodes with ny may
4 episodes with ny may
2 episodes with ny may
5 episodes with ny may
2 episodes with ny may
BUFFALO, NY — May 27, 2026 — A new #research paper was #published in Volume 18 of Aging-US on May 8, 2026, titled “The mediating role of DNA methylation clocks in associations of race, ethnicity, education, income, and occupation with mortality: findings from NHANES 1999-2002.” The study was led by first and corresponding author Hanyang Shen from the Department of Epidemiology and Population Health at Stanford University. In this study, the authors investigated whether DNA methylation aging biomarkers—often called epigenetic aging clocks—may help explain how social inequalities become biologically embedded and contribute to differences in mortality risk. Social factors such as race, ethnicity, educational attainment, household income, and occupation have long been associated with disparities in health outcomes and life expectancy. However, the biological mechanisms linking these social exposures to long-term disease risk and mortality remain incompletely understood. Using nationally representative data from 2,402 adults in the U.S. National Health and Nutrition Examination Survey (NHANES) 1999–2002 linked to mortality follow-up data through 2019, the researchers examined thirteen different DNA methylation biomarkers alongside traditional clinical and behavioral risk factors. The study evaluated whether these epigenetic aging measures mediated associations between social stratification factors and all-cause mortality. The findings showed that several DNA methylation clocks significantly mediated the relationship between social disadvantage and mortality risk. Among all biomarkers examined, GrimAge2 consistently demonstrated the strongest mediation effects, accounting for up to 52% of mortality disparities in some occupational comparisons. DunedinPoAm, a pace-of-aging biomarker, also demonstrated substantial mediation effects across multiple socioeconomic categories. Importantly, the mediation effects observed for several DNA methylation biomarkers frequently exceeded those of traditional clinical risk factors measured in the study, including C-reactive protein and cholesterol-related markers. The results suggest that epigenetic aging measures may capture the cumulative biological effects of multiple social, environmental, behavioral, and physiological stressors simultaneously. “Among all the 13 DNA methylation biomarkers available in NHANES, GrimAge2 consistently exhibited the strongest positive mediation capturing the social disparities on mortality up to 52% (95%CI: 26%-128%), followed by the DunedinPoAm.” Full press release - https://aging-us.net/2026/05/27/dna-methylation-clocks-may-help-explain-how-social-inequality-influences-mortality/ DOI - https://doi.org/10.18632/aging.206377 Corresponding author - Hanyang Shen - hyshen@stanford.edu Abstract video - https://www.youtube.com/watch?v=XObIyirTJok Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206377 Keywords - aging, race and ethnicity, social position, epigenetic aging, mediation analysis, mortality disparities To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 20, 2026 — A new #editorial was #published in Volume 18 of Aging-US on May 18, 2026, titled “Public health in the age of longevity interventions: from prevention to system-wide resilience.” The editorial was authored by Jochen Mierau from the University of Groningen and Aging-US Editor-in-Chief Marco Demaria from the University of Groningen and European Research Institute for the Biology of Ageing (ERIBA). In this editorial, the authors examine how modern public health systems may need to evolve as aging populations increasingly face chronic disease, frailty, multimorbidity, and progressive loss of function rather than the acute infectious diseases that shaped 20th-century medicine. The authors argue that many of the greatest gains in human lifespan historically came not from advanced medical technologies, but from broad public health interventions such as sanitation, vaccination, improved nutrition, occupational safety, safer housing, and access to education. While these measures remain essential, they suggest that modern aging societies now face a different challenge: extending healthspan alongside lifespan. The editorial highlights how today's health risks accumulate gradually across the life course through environmental, metabolic, social, and behavioral exposures. Ultra-processed foods, pollution, tobacco, alcohol, sedentary lifestyles, climate-related stressors, and social isolation are described as contributors to accelerated biological aging and increased vulnerability to chronic disease. The authors emphasize that these interconnected exposures cannot be fully addressed through disease-specific treatment alone. “Rather than representing separate or competing domains, these approaches should be viewed as complementary components of a unified strategy to improve population health across aging societies.” A major focus of the article is the growing scientific interest in longevity-directed interventions that target core biological mechanisms of aging. The authors discuss pathways including cellular senescence, chronic inflammation, metabolic dysfunction, and impaired proteostasis, noting that interventions directed at these processes may help delay or modify multiple age-related diseases simultaneously rather than treating each condition individually after it emerges. Importantly, the editorial emphasizes that longevity interventions should not replace either public health or conventional clinical medicine. Instead, the authors propose a coordinated framework operating across the life course. In this model, public health strategies reduce baseline risk and environmental damage, clinical medicine treats established disease, and longevity-focused therapies may help slow biological decline before major pathology becomes clinically apparent. Figure 1 of the paper (page 2) illustrates this proposed multi-layered framework integrating public health, longevity interventions, and disease-specific care across different stages of life. Full press release - https://www.aging-us.com/news-room/extending-healthspan-through-public-health-and-longevity-medicine DOI - https://doi.org/10.18632/aging.206381 Corresponding author - Marco Demaria - m.demaria@umcg.nl Paper Preview Video - https://www.youtube.com/watch?v=KSjfmxpHer8 To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 19, 2026 — A new #research paper was #published in Volume 18 of Aging-US on May 5, 2026, titled “Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration.” The study was led by first author Kavitha Sadashivaiah and corresponding author Kan Cao from the Department of Cell Biology and Molecular Genetics at the University of Maryland, College Park. In this study, the authors investigated how methylene blue (MB), a long-established mitochondrial-targeted antioxidant, affects human hair follicle stem cells (HFSCs) under conditions of oxidative and metabolic stress. Hair follicle stem cells are essential for maintaining hair growth and regeneration, but aging, ultraviolet radiation, oxidative stress, and metabolic dysfunction can impair their regenerative capacity and contribute to hair thinning and scalp aging. Using cultured human HFSCs, the researchers found that methylene blue significantly enhanced stem cell proliferation and viability while reducing intracellular reactive oxygen species (ROS). Importantly, MB also increased activation of β-catenin signaling, a central pathway involved in hair follicle regeneration, stem cell maintenance, and wound repair. Functional scratch-assay experiments further demonstrated that MB accelerated wound closure and regenerative activity in HFSC cultures. The study also explored how methylene blue interacts with other compounds commonly associated with scalp or hair health. While antioxidant vitamins A and C improved oxidative stress scavenging, they unexpectedly reduced MB-induced β-catenin activation when used in combination. In contrast, minoxidil—the widely used hair growth stimulant—worked synergistically with MB to further enhance β-catenin signaling and improve HFSC viability. “Overall, these findings identify methylene blue as a multifunctional therapeutic candidate that reduces oxidative and metabolic stress while supporting HFSC–mediated hair regeneration.” Another major focus of the paper involved glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications increasingly used for diabetes and weight management. Recent clinical observations have suggested that some patients receiving GLP-1 RA therapy may experience hair thinning or hair loss. The authors demonstrated that increasing GLP-1 RA concentrations caused dose-dependent reductions in HFSC viability in vitro. However, pretreatment with methylene blue substantially protected the stem cells from GLP-1 RA–associated metabolic stress and premature cell death. Beyond stem cell protection, the paper discusses methylene blue's broader potential role in scalp health. Because MB absorbs ultraviolet radiation and has previously demonstrated protective effects against UV-induced DNA damage in skin cells, the authors propose that it may help shield the scalp microenvironment from oxidative injury while supporting regenerative signaling pathways important for hair maintenance. The study also highlights MB's possible antimicrobial properties and its potential influence on scalp microbiome balance. Importantly, the authors emphasize that the findings are based on in vitro cellular models and that further in vivo studies will be necessary before clinical applications can be established. Additional research will be required to define appropriate dosing, pharmacokinetics, long-term safety, and therapeutic efficacy in living systems. Overall, this study identifies methylene blue as a potentially multifunctional therapeutic candidate for supporting hair follicle stem cell health under conditions of oxidative, metabolic, and pharmacologic stress. By combining antioxidant activity with activation of regenerative β-catenin signaling, MB may represent a promising future strategy for protecting scalp health, enhancing hair regeneration, and improving the resilience of aging hair follicle stem cells. DOI - https://doi.org/10.18632/aging.206376
BUFFALO, NY — May 15, 2026 — A new #review was #published in Volume 18 of Aging-US on May 4, 2026, titled “Cellular senescence: from pathogenic mechanisms to precision anti-aging interventions.” The study was led by first author Jian Deng and corresponding author Dong Yang from the Department of Targeting Therapy and Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. In this comprehensive review, the authors examine how cellular senescence contributes to aging and age-related disease across multiple organ systems, while also highlighting the emerging complexity and functional diversity of senescent cell populations. Traditionally, senescent cells have been viewed primarily as harmful byproducts of aging, characterized by irreversible cell-cycle arrest and chronic inflammatory signaling. However, growing evidence suggests that some senescent cells also play beneficial physiological roles in tissue repair, embryonic development, and maintenance of tissue homeostasis. The review outlines how senescence develops in major tissues including the liver, lungs, kidneys, heart, adipose tissue, brain, and skin. Across these organs, aging-related cellular dysfunction is driven by a combination of oxidative stress, mitochondrial dysfunction, DNA damage, chronic inflammation, metabolic stress, telomere shortening, and environmental insults such as ultraviolet radiation and pollution. The authors describe how senescent cells accumulate in highly specialized cell populations—including hepatocytes, endothelial cells, fibroblasts, macrophages, astrocytes, and epithelial cells—where they can disrupt normal tissue architecture and promote chronic disease progression. Importantly, the article emphasizes that senescent cells are highly heterogeneous and should not be treated as a uniform population. Depending on the tissue context and biological environment, senescent cells may exert either protective or harmful effects. For example, certain senescent cells may help limit fibrosis or support wound healing, whereas others drive chronic inflammation, metabolic dysfunction, tissue degeneration, and cancer progression. This growing recognition of functional heterogeneity has prompted a major shift in anti-aging research away from indiscriminate elimination of senescent cells toward more selective and precision-based therapeutic strategies. “Based on these insights, this review summarizes the induction mechanisms of cellular senescence and the subsequent evolution of their functional phenotypes across diverse tissues.” Full press release - https://www.aging-us.com/news-room/precision-anti-aging-strategies-aim-to-target-harmful-senescent-cells-while-preserving-beneficial-ones Paper DOI - https://doi.org/10.18632/aging.206375 Corresponding author - Dong Yang – yangdong@wchscu.cn Abstract video - https://www.youtube.com/watch?v=HkJRwF8mp4A Keywords - cellular senescence, aging mechanisms, functional heterogeneity, precision anti-aging To learn more about the journal, please visit www.Aging-US.com and connect with us on social media at: Bluesky - bsky.app/profile/aging-us.bsky.social ResearchGate - www.researchgate.net/journal/Aging-1945-4589 X - twitter.com/AgingJrnl Facebook - www.facebook.com/AgingUS/ Instagram - www.instagram.com/agingjrnl/ LinkedIn - www.linkedin.com/company/aging/ Reddit - www.reddit.com/user/AgingUS/ Pinterest - www.pinterest.com/AgingUS/ YouTube - www.youtube.com/@Aging-US Spotify - open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – May 13, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case report and literature review.” The study was led by first author Bolat Shalabaev and corresponding author Zhuldyz Kuanysh, both from the National Research Oncology Center, Astana, Kazakhstan. In this report, the authors describe a rare case of high-grade laryngeal leiomyosarcoma (LLMS) in a 64-year-old man who presented with progressive dyspnea and hoarseness caused by a large supraglottic mass. Laryngeal leiomyosarcoma is an exceptionally uncommon malignant tumor of smooth muscle origin, with fewer than 70 cases reported worldwide since it was first described in 1939. Because most laryngeal malignancies are epithelial tumors such as squamous cell carcinoma, diagnosis of LLMS can be particularly challenging and requires extensive histopathological and immunohistochemical evaluation. Imaging studies revealed a heterogeneous laryngeal tumor causing near-complete obstruction of the airway. Histopathological analysis demonstrated high-grade spindle-cell proliferation with marked pleomorphism and pathological mitoses. Immunohistochemical testing showed strong expression of smooth muscle actin (SMA) and vimentin, while markers including CD34, myogenin, cytokeratins 5/6 and 7, and p40 were negative, supporting the diagnosis of high-grade pleomorphic leiomyosarcoma. The patient underwent extended laryngectomy with left neck dissection and formation of a permanent tracheostomy. Comprehensive staging with CT, MRI, and ultrasound showed no evidence of regional or distant metastases. Due to the tumor's aggressive pathological features—including a Ki-67 proliferation index reaching 60%—the multidisciplinary tumor board recommended adjuvant chemotherapy with doxorubicin and ifosfamide following surgery. “Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients.” Postoperative pathology confirmed a high-grade pleomorphic leiomyosarcoma classified as pT3N0M0 according to the AJCC 8th edition staging system. Importantly, surgical margins were negative, and no metastatic involvement was identified in the five examined lymph nodes. At the most recent follow-up, 12 months after surgery and completion of chemotherapy, the patient remained alive and free of recurrence or metastasis. The authors also reviewed recently published LLMS cases reported between 2021 and 2024. Their analysis confirmed persistent male predominance, frequent involvement of the glottic and supraglottic regions, and highly variable clinical outcomes ranging from long-term disease-free survival to rapid metastatic progression. The report further highlights the central role of immunohistochemistry in differentiating leiomyosarcoma from other spindle-cell neoplasms of the head and neck. Importantly, the study emphasizes that complete surgical resection with histologically negative margins remains the most important factor associated with favorable outcomes. While the role of chemotherapy in laryngeal leiomyosarcoma remains controversial, the authors note that individualized multidisciplinary treatment approaches may be particularly valuable in patients with high-grade or high-risk disease features. Overall, this report contributes important clinical insight into one of the rarest malignancies of the larynx. As the first documented case of laryngeal leiomyosarcoma reported from Central Asia, the study expands the limited global literature on this disease and underscores the importance of coordinated multidisciplinary care, detailed pathological evaluation, and long-term surveillance in optimizing patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28862 Correspondence to - Zhuldyz Kuanysh - zhuldyzkuanysh@icloud.com Abstract video - https://www.youtube.com/watch?v=i3AoqIXo3Ys
BUFFALO, NY — May 12, 2026 — A new #research paper was #published in Volume 18 of Aging-US on May 4, 2026, titled “Host immunosenescence compromises Mycobacterium tuberculosis clearance.” The study was led by first author Falak Pahwa and corresponding author Ranjan Kumar Nanda from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India. In this study, the authors investigated how aging alters immune responses during tuberculosis infection and treatment. Tuberculosis remains one of the world's deadliest infectious diseases, and older adults are particularly vulnerable due to immunosenescence, the gradual decline of immune function that occurs with aging. Despite the growing burden of tuberculosis in aging populations worldwide, most experimental models continue to rely on young adult animals that do not accurately reflect immune aging. Using multiple age groups of C57BL/6 mice, the researchers examined how aging affects the body's ability to control Mycobacterium tuberculosis during treatment with rifampicin and isoniazid (RIF-INH), two cornerstone anti-tuberculosis drugs. While young and older mice initially showed similar bacterial burden following infection, older mice demonstrated significantly delayed bacterial clearance in the lungs during the early phase of treatment. Importantly, the study identified several age-associated immune abnormalities linked to impaired bacterial clearance. Older mice exhibited chronic inflammatory signaling, altered T cell responses, accumulation of T-follicular cytotoxic (TFC)-like cells, and evidence of mitochondrial dysfunction within immune cells. Proteomic analysis of splenic CD4+CD44+ T cells further revealed dysregulation of mitochondrial proteins involved in cellular metabolism and immune function. “Collectively, these findings suggest that age-associated immune alterations may disrupt immunometabolic pathways, thereby contributing to the delayed Mtb clearance.” The researchers also observed that older mice maintained elevated inflammatory cytokine levels and developed persistent lung inflammation even after treatment had begun. At the same time, key protective immune responses appeared functionally impaired, suggesting that aging may disrupt the balance between inflammation and effective pathogen control. Together, these findings suggest that age-related immunometabolic dysfunction may play a major role in the reduced treatment response observed in older hosts. Notably, the study found that delayed bacterial clearance in older mice did not appear to result primarily from liver toxicity or impaired drug metabolism. Instead, the evidence suggested that age-related immune dysfunction itself was the dominant factor limiting effective bacterial elimination during therapy. The paper further highlights the emerging importance of mitochondrial health in immune cell function during aging. The authors propose that targeting age-associated immunometabolic defects and mitochondrial dysfunction may represent a promising strategy for improving tuberculosis treatment outcomes in elderly populations. Overall, this study provides new insight into why older adults experience poorer tuberculosis outcomes despite receiving standard therapy. As global populations continue to age, understanding how immunosenescence alters infectious disease responses may become increasingly important for the development of more effective treatment strategies and age-adapted therapeutic interventions. DOI - https://doi.org/10.18632/aging.206374 Corresponding author - Ranjan Kumar Nanda - ranjan@icgeb.res.in Abstract video - https://www.youtube.com/watch?v=isPD8ZmUjv8 Website - https://www.Aging-US.com MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – May 11, 2026 – A new #editorial was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Artificial intelligence in nutritional oncology: From isolated screening tools to agentic intervention systems.” The editorial was authored by first author Arnab Sarkar and corresponding author Yashbir Singh-Wolkenhauer, who is affiliated with the Mayo Clinic Department of Radiology. In this editorial, the authors examine how emerging forms of artificial intelligence may help address one of oncology's most persistent yet underrecognized challenges: cancer-related malnutrition. Although nutritional complications affect a large proportion of cancer patients and are associated with poorer treatment tolerance, prolonged hospitalizations, and reduced survival, access to specialized nutritional care remains severely limited in many healthcare settings. The article focuses on the growing role of “agentic AI,” a new class of autonomous AI systems capable of reasoning across complex clinical information, using external tools, maintaining memory, and adapting to changing patient conditions over time. Unlike conventional AI tools that perform isolated tasks such as malnutrition screening or dietary counseling, agentic AI systems are designed to coordinate multiple functions simultaneously and support ongoing clinical decision-making throughout a patient's treatment course. “Where a conventional model answers the question “Is this patient malnourished?”, an agentic system pursues the goal ‘Optimize this patient's nutritional status throughout their treatment course,' autonomously decomposing that objective into sensing, reasoning, and acting steps.” The authors outline a proposed multi-agent framework for nutritional oncology that includes specialized AI agents responsible for nutritional screening, dietary planning, treatment-nutrition interaction monitoring, and patient engagement. These agents would operate together under a centralized coordination system capable of integrating laboratory data, imaging findings, treatment-related side effects, food preferences, wearable device data, and electronic health records in real time. The proposed architecture is illustrated in Figure 1 of the paper (page 2), which depicts how multiple AI agents could coordinate patient-centered nutritional support across oncology workflows. Importantly, the editorial emphasizes that clinical oversight remains essential. The authors propose a graduated autonomy model in which lower-risk functions, such as recipe recommendations or symptom-triggered dietary advice, may operate with minimal supervision, while higher-risk decisions involving enteral or parenteral nutrition would continue to require direct clinician authorization. The article also highlights several major barriers that must be addressed before widespread clinical implementation becomes possible. These include AI hallucination risk, regulatory uncertainty, privacy concerns involving integrated patient data, and the potential for algorithmic bias when systems are trained predominantly on Western dietary and clinical datasets. The authors further note that no randomized controlled trials have yet evaluated AI-driven nutritional interventions against major oncologic outcomes such as survival or treatment completion. Overall, the editorial presents agentic AI as a potentially important next step in supportive cancer care. By integrating nutritional assessment, personalized dietary planning, and longitudinal patient monitoring into coordinated AI-driven systems, these technologies may help close longstanding gaps in oncology nutrition services while supporting more individualized and responsive patient care. DOI - https://doi.org/10.18632/oncotarget.28874 Correspondence to - Yashbir Singh-Wolkenhauer - singh.yashbir@mayo.edu Introduction video - https://www.youtube.com/watch?v=sVKhRSr5xaY Website: https://www.oncotarget.com MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 7, 2026 — A new #research paper was #published in Volume 18 of Aging-US on April 24, 2026, titled “The BHARAT study: a multi-modal, multi-omics investigation of aging signatures in the Indian population.” The study was led by first author Suramya Asthana and corresponding author Deepak Kumar Saini from the Indian Institute of Science (IISc). The authors introduce the BHARAT Study (Biomarkers of Healthy Aging, Resilience, Adversity, and Transitions), India's first large-scale, discovery-driven multi-omics cohort focused on understanding biological aging in the Indian population. The initiative was developed to address a major gap in aging research, as most existing biological age models and aging datasets have been derived primarily from Western populations. The BHARAT study is a multi-center, cross-sectional observational cohort that integrates clinical, molecular, lifestyle, and environmental data from participants across diverse demographic groups in India. The initiative aims to enroll healthy volunteers spanning multiple age groups, with balanced rural-urban and sex representation. Biological samples—including blood, urine, stool, cheek swabs, and hair—will undergo extensive multi-omics profiling, including epigenomics, proteomics, metabolomics, lipidomics, metagenomics, and immune phenotyping. “By generating interoperable, high-resolution data suited for mechanistic modelling and machine learning, BHARAT contributes a resource of global relevance that would be capable of refining universal models of aging biology while revealing novel, population-specific pathways that inform prevention and intervention strategies.” The initiative uses a hub-and-spoke framework centered at the Indian Institute of Science, which serves as the central hub for biobanking, multi-omics analysis, computational integration, and AI-driven modeling. Clinical and community partners across India contribute participant recruitment, clinical assessments, and biological sampling, enabling the study to capture the country's extraordinary genetic, environmental, dietary, and socioeconomic diversity. A major focus of the study is the development of population-specific biological aging signatures and predictive models tailored to Indian populations. Researchers aim to identify biomarkers associated with resilience, frailty, and age-related decline while also recalibrating biological clocks that may not accurately reflect aging trajectories in non-Western populations. The study further seeks to establish standardized reference datasets and create scalable infrastructure for future longitudinal aging research in India. Importantly, the BHARAT study combines untargeted discovery-based omics technologies with advanced artificial intelligence and machine learning approaches. By integrating molecular data with clinical and lifestyle information, the initiative aims to improve understanding of how biological aging is shaped by genetics, environment, nutrition, infection burden, and social determinants of health. Overall, this study establishes a comprehensive framework for aging research in one of the world's most diverse populations. By generating large-scale, population-specific biological datasets, the BHARAT initiative may help advance precision aging research, improve risk prediction models, and support the development of more personalized approaches to healthy aging and disease prevention. DOI - https://doi.org/10.18632/aging.206373 Corresponding author - Deepak Kumar Saini - deepaksaini@iisc.ac.in Abstract video - https://www.youtube.com/watch?v=qH2AbitDURQ Website - https://www.Aging-US.com MEDIA@IMPACTJOURNALS.COM
A powerful conversation on authenticity, resilience, and rebuilding after rock bottom—why becoming who you are is a lifelong journey.In this episode:Living with authenticity—not perfectionFrom the Jacksonville Jaguars to losing everything—and rebuildingMotivation vs. inspiration (and why it matters)How ego can derail success—and what it takes to recoverWhy rock bottom can become a turning pointThe power of perseverance and resilienceInvesting in yourself at every stageGrowing, evolving, and staying true to who you are
BUFFALO, NY – May 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.” The study was led by first author Cameron B. Speyer from the UCLA David Geffen School of Medicine, and corresponding author Joseph G. Crompton, who holds appointments at both the UCLA David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center. In this report, the authors describe a rare and clinically informative case of a small bowel gastrointestinal stromal tumor (GIST) harboring two genetic alterations that are typically considered mutually exclusive. GISTs are most commonly driven by activating mutations in the KIT or PDGFRA genes, which confer sensitivity to targeted therapies such as imatinib. In contrast, tumors associated with succinate dehydrogenase (SDH) deficiency represent a distinct subgroup that is generally resistant to these treatments. The patient, a 68-year-old man, presented with progressive abdominal pain, bloating, and constipation. Imaging studies revealed a large heterogeneous mass in the lower abdomen measuring up to 18 cm. A biopsy confirmed a spindle cell neoplasm consistent with GIST, with immunohistochemical staining positive for CD117 and DOG1. Genomic analysis identified both a KIT exon 9 duplication (A502_Y503) and a germline SDHC mutation (p.R50C)—a highly unusual combination. Despite the presence of the SDHC mutation, which is typically associated with resistance to therapy, the patient demonstrated a strong response to high-dose imatinib. After six months of neoadjuvant treatment, imaging showed a marked reduction in tumor size and metabolic activity, enabling successful surgical resection. “This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.” Pathologic examination of the resected tumor revealed significant treatment response, including extensive necrosis and reduced tumor viability. Notably, immunohistochemistry demonstrated retained SDHB expression, indicating preserved SDH complex function despite the identified germline mutation. The case highlights an important clinical insight: not all detected genetic alterations contribute equally to tumor behavior. While SDH-deficient GISTs are typically resistant to imatinib, this tumor behaved in a manner consistent with KIT-driven disease, underscoring the importance of interpreting molecular findings within their clinical and pathological context. Overall, this report emphasizes the need for integrated molecular analysis in cancer diagnosis and treatment. As next-generation sequencing becomes more widely used, clinicians may encounter tumors with multiple coexisting mutations. Determining the dominant oncogenic driver is essential for selecting the most effective therapy and improving patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 5, 2026 — A new #research paper was #published in Volume 18 of Aging-US on April 13, 2026, titled “Cross species activity of TERT human telomerase component.” The study was led by co–first authors Raúl Sánchez-Vázquez and Paula Martínez, with María A. Blasco serving as corresponding author, from the Spanish National Cancer Centre (CNIO), Madrid, Spain. In this study, the researchers explored a key question in aging and regenerative medicine: can the human telomerase protein function effectively in other species commonly used in preclinical research? Telomerase plays a central role in maintaining chromosome integrity by preventing telomere shortening—a process closely linked to cellular aging and disease. To investigate this, the team introduced the human telomerase catalytic subunit (TERT) into primary lung fibroblasts from several mammalian species, including monkey, pig, rabbit, rat, dog, and mouse. They then assessed both biochemical activity and the ability of telomerase to extend telomeres over time. The results revealed a clear distinction between biochemical compatibility and true biological function. In vitro, human TERT was able to form active complexes with telomerase RNA from several species, including monkey, pig, rabbit, and rat. However, this activity did not always translate into effective telomere maintenance in living cells. Notably, only human and non-human primate cells showed progressive telomere lengthening over time. In contrast, other species—even those showing initial enzymatic activity—failed to sustain telomere extension during long-term culture. In some cases, telomeres continued to shorten, suggesting that functional integration of telomerase depends on additional species-specific factors. The study also uncovered important limitations in commonly used animal models. Mouse and canine cells did not support human TERT activity, and in some cases, expression of the human enzyme led to reduced cell viability and signs of cellular stress. “These results reveal that only non-human primate cells support full functional activity of the human telomerase protein in a cellular context, underscoring their suitability as preclinical models for telomerase-based therapeutic strategies.” Importantly, the findings highlight that successful telomerase activity in a test tube does not necessarily reflect what happens inside a living cell. The recruitment, regulation, and function of telomerase depend on a complex network of interacting proteins and cellular processes, many of which differ across species. Overall, this study provides important insight into the challenges of translating telomerase-based therapies from preclinical models to humans. By identifying non-human primates as the most compatible system, the work offers a clearer path forward for developing therapies aimed at treating telomere-related diseases and age-associated conditions. DOI - https://doi.org/10.18632/aging.206372 Corresponding author - Maria A. Blasco - mblasco@cnio.es Abstract video - https://www.youtube.com/watch?v=XxjjId5i_Ww Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, telomeres, telomerase To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Sports and science go hand in hand, especially when it comes to softball and baseball. Join Molly and co-host Caris as they answer more of your questions about these two ballgames. Like why are bats measured in ounces? Or why do some players wear black paint under their eyes? Plus, we’ll hear more of your chants and guess an all new Mystery Sound. Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! April 25 - Marines Memorial, San Francisco, CA (2nd show added!) April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON (2nd show added!) June 6 - Michigan Theater, Ann Arbor, MI June 20 - Southern Theater, Columbus, OH June 21 - Turner Hall Ballroom, Milwaukee, WI Click here for a transcript of this episode.See omnystudio.com/listener for privacy information.
Backdoor Media presents: HUMP! Wednesdays with DJSOUL - A 60-minute, commercial-free HipHop; sometimes HOUSE, mixtape by LGBTQ recording artist/producer Tony DJSOUL Dobson, featuring the best LGBTQ+ voices in HipHop - Every Wednesday @ Midnight (EST)“To be young, gifted, and Black” — The Last PoetsB! NOTED - Originally recorded in South Ozone Park, Queens, NY - May 11, 20111 God Speak - Analog LUST2 Wild'n Cuz I'm Young - Kid Cudi/Kanye West3 Disgusting - J. Cole4 The Type - Curren$y/The Alchemist/Prodigy5 Gone - Sonny “Bang Bang” Lewis (RIP)6 I Don't Deserve You - Lloyd Banks/Jeremih7 Luke Skywalker - Omarion/Method Man8 6 Foot 7 Foot - Lil Wayne/Cory Gunz9 Everyday (Coolin') - Swizz Beatz/Eve10 Eric B. Is President - Eric B./Rakim11 Bounce Back - Pusha T12 Shame - Jill Scott/Eve/The A Group13 What Cha Gonna Do with My Lovin' - Stephanie Mills14 Raw - Big Daddy Kane15 Paper Thin - MC Lyte16 Jam On The Groove - Ralph MacDonald17 You'll Never Find Another Love Like Mine - Lou Rawls18 I Want Your Love - Chic19 Super Sporm - Captain Sky20 Joyous - Pleasure21 Related to What Chant - The Last Poets “HipHop Is Fine Art!” — Tony DJSOUL DobsonTIP JAR - Thank YOU!CASH APP $TonyDJSOULDobson
Baseball and softball are both a feat of physics, from the curve of a pitch to the swing of a bat. Today, we’re exploring the science of these popular pastimes. Join Molly and co-host Kian as they learn about curve balls and the stuff inside a ball. Plus, our listeners share their chants for Team Science! Oh, and what’s that noise? It’s a brand new mystery sound. Play ball! Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! April 11 - Walker Theater, Chattanooga, TN April 12 - Carolina Theater, Durham, NC April 25 - Marines Memorial, San Francisco, CA (2nd show added!) April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON (2nd show added!) Click here for an episode transcriptSee omnystudio.com/listener for privacy information.
Ever look closely at a raspberry and notice it could use a shave? Those tiny hairs are actually super important. And thankfully totally edible. Join Molly and co-host Zoe-Samarah as they learn all about this fantastic little fruit, and why some raspberry flavored foods are actually colored blue. All that and a Mystery Sound that’ll feel like a snack for the ears! Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! April 11 - Walker Theater, Chattanooga, TN April 12 - Carolina Theater, Durham, NC April 25 - Marines Memorial, San Francisco, CA (2nd show added!) April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON (2nd show added!) Click here for an episode transcriptSee omnystudio.com/listener for privacy information.
Have you heard of the Bermuda Triangle? It’s an area of the Atlantic Ocean that some people think can make ships and planes mysteriously disappear. In this episode, Marc and Sanden, aka the Hoax Hunters, investigate this weird and wild patch of water. Turns out the Triangle isn’t as unusual as it seems. Plus, Molly tries to stump the Hoax Hunters with a new mystery sound. Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! March 28 - Center Stage, Atlanta, GA March 29 - Amaturo Theater, Fort Lauderdale, FL April 11 - Walker Theater, Chattanooga, TN April 12 - Carolina Theater, Durham, NC April 25 - Marines Memorial, San Francisco, CA (2nd show added!) April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON (2nd show added!) Click here for an episode transcriptSee omnystudio.com/listener for privacy information.
Flowers are famous for their smells. Most are sweet, but a few are downright stinky. Either way, the science of how and why they make these scents is fascinating. Join Molly and co-host Isla as they learn about pollinators, flower smells and the mighty corpse flower! Plus a smell for your ears: the Mystery Sound! Guest: Dr Kelsey Byers, evolutionary chemical ecologist and group leader at the John Innes Center. Want to support the show? Join Smarty Pass to listen to ad-free episodes or donate! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! March 7 - Turner Hall Ballroom, Milwaukee, WI March 8 - Fitzgerald Theater, St. Paul, MN March 28 - Center Stage, Atlanta, GA March 29 - Amaturo Theater, Fort Lauderdale, FL April 11 - Walker Theater, Chattanooga, TN April 12 - Carolina Theater, Durham, NC April 25 - Marines Memorial, San Francisco, CA April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON Click here for an episode transcriptSee omnystudio.com/listener for privacy information.
Every spring we set our clocks one hour forward. Every fall we move them one hour back. It’s a strange ritual when you think about it, so why do we do it? Join Molly and co-host Ava as they explore the seasons and why days are shorter in the winter and longer in the summer. We’ll hear about the history of Day Light Saving and play a game. And it’s always time for a Mystery Sound! So set an alarm so you don’t forget to tune in to this episode! Want to support Brains On and all of the shows in the Brains On Universe? Sign up for Smarty Pass. You'll get ad-free episodes of all our shows, bonus content, virtual hangouts, discounts on merch and more! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! March 7 - Turner Hall Ballroom, Milwaukee, WI March 8 - Fitzgerald Theater, St. Paul, MN March 28 - Center Stage, Atlanta, GA March 29 - Amaturo Theater, Fort Lauderdale, FL April 11 - Walker Theater, Chattanooga, TN April 12 - Carolina Theater, Durham, NC April 25 - Marines Memorial, San Francisco, CA April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ON Click here for a transcript of this episode.See omnystudio.com/listener for privacy information.
HARVEY, our omnipresent virtual voice assistant, gets a software update that makes him go bananas for bananas. And if we talk about anything except bananas, he turns the microphones off! We talk to geneticist Dr. Janina Jeff about how much DNA we share with a banana, find out why bananas make other fruits ripen, how bananas grow, and where that slipping on a banana peel joke came from. Speaking of jokes, we'll hear a bunch of banana jokes from listeners too! Plus: The Moment of Um answers the question: "Why are peaches fuzzy?" You can hear more from Dr. Jeff on her podcast In Those Genes. Silent film expert Lea Stans has a wonderful blog post about the history of the banana peel joke that you can read right here. You can see some of those early comics that featured the joke! https://www.youtube.com/watch/RMDgmHB4znc Want to support Brains On and all of the shows in the Brains On Universe? Sign up for Smarty Pass. You'll get ad-free episodes of all our shows, bonus content, virtual hangouts, discounts on merch and more! Want to see Brains On live?!? We are probably coming to a city near you. For a complete list of shows and links to tickets head to our events page. More shows announced soon! March 7 - Turner Hall Ballroom, Milwaukee, WI March 8 - Fitzgerald Theater, St. Paul, MN March 28 - Center Stage, Atlanta, GA March 29 - Amaturo Theater, Fort Lauderdale, FL April 11 - Walker Theater, Chattanooga, TN April 12 - Carolina Theater, Durham, NC April 25 - Marines Memorial, San Francisco, CA April 26 - Newmark Theater, Portland, OR May 30 - Electric City, Buffalo, NY May 31 - Royal Theatre, Toronto, ONSee omnystudio.com/listener for privacy information.
The U.S. Transportation Department on Friday threatened to pull tens of millions of dollars in funding from New York over commercial driver licenses improperly issued to non-U.S. citizens. USDOT said New York must take actions to address concerns about immigrant truck drivers within 30 days or the state could lose federal highway funding. The U.S. Justice Department said on Friday it had filed lawsuits against Colorado, Hawaii, Massachusetts and Nevada after the states failed to provide their voter registration lists to the department. The department's Civil Rights Division also filed a lawsuit against Fulton County, Georgia, for records related to the 2020 election, it said in a statement.
BUFFALO, NY - May 23, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma." The study, led by first authors Leonardo Gomes da Fonseca from Hospital das Clínicas, Universidade de São Paulo, Brazil, and Federico Piñero from Hospital Universitario Austral, Argentina, investigated how patients with advanced liver cancer in Latin America respond to a widely used immunotherapy combination. The researchers found that although a minority of patients developed immune-related side effects, these events did not significantly impact overall survival. Their findings highlight the importance of early recognition and careful management of such side effects in real-world clinical settings. Liver cancer is a leading cause of cancer deaths worldwide, with limited treatment options for patients diagnosed at an advanced stage. Immunotherapy, particularly the combination of atezolizumab and bevacizumab, has become a standard approach. However, these treatments can sometimes trigger the body's immune system to attack healthy organs, leading to what are called immune-related adverse events, or irAEs. Until now, little data existed on how frequently these events occur in Latin American patients and whether they impact treatment outcomes. The researchers followed 99 patients from Argentina, Brazil, Chile, and Colombia, most of whom had cirrhosis or underlying liver disease. They received atezolizumab and bevacizumab for a median duration of six months. The researchers reported that only 18% of the patients experienced immune-related side effects, most commonly affecting the liver (hepatitis) and thyroid (thyroiditis). Most of these cases were mild or moderate, and half of them resolved completely within a month. Only eight patients needed treatment with steroids to control the immune response. Importantly, the occurrence of immune-related side effects did not affect how long patients survived after starting treatment. The median survival was the same—18.5 months—for both those who experienced irAEs and those who did not. This result suggests that while irAEs require careful management, they may not reduce the overall benefits of immunotherapy. Another significant finding was that patients with higher levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, were more likely to experience these side effects. This information could help clinicians identify patients who need closer control during treatment. “Notably, baseline alpha-fetoprotein (AFP) values ≥400 ng/ml were significantly associated with the development of irAEs.” The study also points to key differences between clinical trial results and real-world experiences. While clinical trials report higher rates of side effects, this real-world data showed a lower incidence, possibly due to less intensive monitoring or differences in how side effects are documented in everyday practice. In summary, this study highlights that patients require ongoing vigilance and individualized care when treating liver cancer with immunotherapy. It provides valuable information to healthcare providers in Latin America and other regions with similar patient populations, aiming to improve outcomes while minimizing risks. DOI - https://doi.org/10.18632/oncotarget.28721 Correspondence to - Federico Piñero - fpinerof@cas.austral.edu.ar To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 23, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 1, 2025, titled “Examining frailty phenotypes of community-dwelling older adults in Taiwan using the falls risk for older people in the community – Taiwan version (Tw-FROP-Com).” A research team led by first author Ya-Mei Tzeng and corresponding authors Yu-Tien Chang and Yaw-Wen Chang from the National Defense Medical Center studied older adults in Taiwan and found that unintentional weight loss is the most significant individual predictor of fall risk among the common signs of frailty. This finding highlights the importance of early detection and tailored interventions to reduce fall-related injuries among aging populations. Falls are a major cause of injury-related death in seniors, especially in low- and middle-income countries. In Taiwan, they rank as the second leading cause of accidental death among those aged 65 and older. The researchers evaluated five signs of frailty—weakness, slowness, exhaustion, low physical activity, and unintentional weight loss—using a locally adapted fall risk screening tool, Tw-FROP-Com. Frailty is a condition marked by reduced strength, stamina, and resilience, making older adults more vulnerable to accidents and illness. The study analyzed data from 375 older adults participating in a fall prevention program in Keelung City. Of these, 18.7% were classified as frail, and nearly one-third had experienced a fall in the past year. All five frailty signs were associated with increased fall risk, but statistical analysis showed that unintentional weight loss had the strongest association, even after adjusting for factors like age and previous falls. Rather than relying on a broad frailty label, this study found that analyzing each frailty feature individually provided more accurate predictions of fall risk. Weight loss, in particular, was also associated with conditions such as malnutrition, muscle decline, or chronic illness. “Treating frailty as five distinct components provided a more precise prediction of fall risk than using a dichotomous frailty measure (Yes/No).” The findings support the use of accessible screening tools like Tw-FROP-Com in everyday healthcare settings. Because it does not require complex equipment or physical testing, it can be widely applied to identify older adults at risk. Interventions such as nutritional support, physical activity, and weight monitoring can then be offered before a fall occurs. The researchers recommend that public health programs and healthcare providers focus on each specific frailty sign, especially unintentional weight loss, rather than relying only on overall frailty status. As the global population ages, targeted fall prevention strategies like these may help older adults live healthier, more independent lives. Paper DOI: https://doi.org/10.18632/aging.206231 Corresponding authors: Yu-Tien Chang – greengarden720925@gmail.com; Yaw-Wen Chang- yawwenc@office365.ndmctsgh.edu.tw Keywords: aging, frailty, fall risk, fried frailty criteria, older adults, Tw-FROP-Com Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, epigenetics, DNA methylation, diet, biological clock To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY - May 21, 2025 – A new #review was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy." Researchers from the University of California, Irvine, led by Nazmul Hasan, reviewed recent clinical and scientific advances in combining radiation therapy with immunotherapy for bladder cancer. The article summarizes growing evidence that this combined approach may strengthen the immune response and improve long-term disease control. This strategy is especially important for patients who are not candidates for surgery or who respond poorly to conventional treatments. Bladder cancer is a serious and frequent condition, particularly affecting older men. Traditional treatments—surgery, chemotherapy, and radiation—can be effective, but they often fail to prevent cancer reappearance in advanced cases. The review explores how combining radiation and immunotherapy could improve outcomes by helping the immune system detect and destroy cancer cells more effectively. Radiation therapy destroys cancer cells and triggers the release of tumor signals that attract immune cells. Immunotherapy, including drugs like pembrolizumab and nivolumab, helps the immune system work better by blocking proteins that allow cancer to evade detection. Used together, these treatments may produce a stronger, more widespread anti-tumor effect, even at distant sites not directly targeted by radiation. The review discusses several clinical trials that support this approach. One phase II study reported that combining radiation with the immunotherapy drug durvalumab led to promising survival rates and manageable side effects. Another trial in Australia tested pembrolizumab with radiation and chemotherapy, resulting in high tumor control and extended patient survival. However, the review also points out that other trials showed serious side effects when high doses or multiple immunotherapy drugs were used at once. "Joshi et al. performed a phase II study to determine the safety and efficacy of combining radiation therapy with durvalumab, a PD-L1 inhibitor, in patients who were ineligible for surgery or cisplatin-based chemotherapy." While the combination approach is promising, the authors emphasize that more research is needed to refine this treatment strategy. One major challenge is determining which patients are most likely to benefit. Future studies should focus on identifying reliable biomarkers, such as tumor mutation burden or immune activity, to guide personalized treatment plans. This review highlights the potential of combining radiation and immunotherapy to improve outcomes for bladder cancer patients. With continued research and careful treatment design, this approach could offer new treatment options for those facing aggressive or hard-to-treat forms of the disease. DOI - https://doi.org/10.18632/oncotarget.28723 Correspondence to - Nazmul Hasan - nhasan1@hs.uci.edu Video short - https://www.youtube.com/watch?v=AxrZhIUXrOQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28723 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, bladder cancer, immunotherapy, radiation, microenvironment, abscopal To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 20, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 17, 2025, titled “Dietary associations with reduced epigenetic age: a secondary data analysis of the methylation diet and lifestyle study.” In this study, researchers led by first author Jamie L. Villanueva from the University of Washington and the National University of Natural Medicine, along with corresponding author Ryan Bradley from the National University of Natural Medicine and University of California, investigated how diet influences epigenetic aging. They found that certain plant-based foods containing natural compounds called methyl adaptogens were associated with a decrease in epigenetic age. This effect was measured using DNA methylation, a marker that reflects how the body ages at the cellular level. The findings suggest that targeted food choices may help slow the aging process. Epigenetic age refers to how old a person's cells appear biologically, rather than their actual age in years. DNA methylation patterns, which are chemical tags on DNA, can indicate whether someone is aging faster or slower than expected. For this study, researchers used Horvath's epigenetic clock, a widely accepted tool, to measure changes in epigenetic age. The analysis included healthy men aged 50 to 72 who had previously completed an eight-week program featuring a plant-based, nutrient-rich diet, along with guidance on exercise, sleep, and stress management. Researchers focused on individual dietary differences to understand why some participants experienced greater improvements in epigenetic age than others. The study found that those who ate higher amounts of methyl adaptogen foods—including turmeric, rosemary, garlic, berries, green tea, and oolong tea—experienced greater reductions in epigenetic age. These benefits remained significant even after accounting for weight changes and participants' starting epigenetic age, suggesting that the foods themselves had a direct impact on aging markers. “In hierarchical linear regression, foods investigated as polyphenolic modulators of DNA methylation (green tea, oolong tea, turmeric, rosemary, garlic, berries) categorized in the original study as methyl adaptogens showed significant linear associations with epigenetic age change (B = -1.21, CI = [-2.80, -0.08]), after controlling for baseline epigenetic age acceleration and weight changes.” The natural compounds in methyl adaptogen foods are known to influence how genes behave by affecting DNA methylation. Previous studies have shown that these compounds may support healthy aging and help lower the risk of conditions such as heart disease and cognitive decline. While this study involved a relatively small group of middle-aged men, it adds knowledge to growing global research showing that diets rich in polyphenols—found in vegetables, fruits, and teas—are associated with slower aging. These findings support earlier results from studies on Mediterranean and traditional Japanese diets, both known for their health benefits. Future research should include larger and more diverse populations and use updated epigenetic aging tools to confirm these results. Based on current evidence, this study highlights a practical, food-based strategy that may help reduce epigenetic aging and support long-term health. DOI - https://doi.org/10.18632/aging.206240 Corresponding author - Ryan Bradley - rbradley@nunm.edu To learn more about the journal, connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – May 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.” In this study, a team from Foresight Diagnostics led by first author Nina Klimova and corresponding author Laura Hyland validated a new DNA-based blood test designed to detect minimal residual disease (MRD) in patients with B-cell cancers. This assay uses a highly sensitive method called Phased Variant Enrichment and Detection Sequencing (PhasED-Seq) to find tiny fragments of tumor DNA in the blood. Its ultra-sensitive detection capabilities offer a powerful tool for early cancer detection, monitoring treatment response, and predicting cancer reappearance. B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL), are among the most prevalent blood cancers. Although many patients respond to initial treatment, up to 40% relapse. Standard monitoring methods such as imaging scans often miss low levels of cancer cells, creating a need for more precise tools. This study introduces a non-invasive blood test that improves the detection of MRD, a critical factor in guiding follow-up care and early intervention. The test works by tracking unique groups of mutations known as phased variants in tumor DNA. These mutations are more specific to cancer and allow for highly accurate identification of tumor fragments in the bloodstream. The PhasED-Seq-based MRD assay was tested on three types of samples. First, blood plasma from healthy individuals was used to confirm the test does not give false positives. Second, researchers created controlled samples by mixing tumor DNA from lymphoma patients with healthy DNA to measure how sensitive and precise the test is. Finally, blood samples from patients with B-cell lymphoma were used to compare the new test to an existing method. Across all sample types, the PhasED-Seq-based MRD assay demonstrated exceptional performance—capable of detecting fewer than one cancer DNA molecule per million normal DNA fragments. It also demonstrated a very low false positive rate and over 96% reproducibility across different laboratory conditions. Compared to an existing method, the new PhasED-Seq assay showed more than 90% agreement in positive results and nearly 78% agreement in negative results. In cases where the tests disagreed, the new method aligned more closely with actual clinical outcomes, including whether patients relapsed or stayed in remission. “The background error rate of the PhasED-Seq-based MRD assay was 1.95E-08, or 1.95 mutant molecules in 100 million informative molecules.” The findings support the use of PhasED-Seq-based MRD assays in routine clinical practice. It could be especially useful for identifying patients who need additional treatment even when imaging results appear normal. This aligns with updated clinical guidelines that encourage the use of blood-based DNA tests to supplement traditional scans in lymphoma care. This study offers strong evidence that the PhasED-Seq-based MRD assay is a precise, reliable, and clinically relevant tool. By detecting signs of cancer earlier and more accurately, it may help clinicians tailor treatments to individual patients and improve long-term outcomes in B-cell malignancies. DOI - https://doi.org/10.18632/oncotarget.28719 Correspondence to - Laura Hyland - laura.hyland@foresight-dx.com Video short - https://www.youtube.com/watch?v=8hdh3G5zvlc Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY - May 14, 2025 – A new #review paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Relationship between ABO blood group antigens and Rh factor with breast cancer: A systematic review and meta-analysis." A comprehensive study, led by first authors Rahaf Alchazal from Yarmouk University and Khaled J. Zaitoun from Johns Hopkins University School of Medicine and Jordan University of Science and Technology, examined the potential link between blood type and breast cancer. The research team conducted a systematic review and meta-analysis of 29 previously published studies, involving more than 13,000 breast cancer patients and over 717,000 controls. “Researchers searched for studies on breast cancer patients and ABO blood groups across four major databases: PubMed, Scopus, Web of Science, and Google.“ Breast cancer is the most common cancer among women worldwide. Identifying risk factors is vital for early detection and prevention. While many studies have explored lifestyle and genetic causes, this analysis focused on the ABO blood group system. By pooling global data, the researchers found that blood type A was the most common among breast cancer patients and was significantly associated with an 18% increased risk compared to type O. The study did not find a significant association between breast cancer and blood types B, AB, or Rh factor. Although the results do not prove causation, they point to a biological pattern worth further investigation. Blood group antigens are proteins found on the surface of cells, including breast tissue. These molecules may influence how cancer develops and spreads by interacting with the immune system or affecting cell behavior. This meta-analysis is the most extensive review to date on this topic, based on studies conducted across Asia, Europe, Africa, and the Americas. While previous research found unclear conclusions, this large-scale evaluation provides stronger evidence for a possible connection between blood type A and breast cancer risk. Researchers note that regional differences, genetic diversity, and study quality may affect individual results. Nevertheless, the overall trend supports considering blood type A as a potential risk marker. This insight could help shape screening guidelines, encouraging earlier or more frequent checkups for women with this blood type. Further research is needed to understand why blood type A may play a role in cancer development. Future studies may explore genetic mechanisms, immune responses, and other biological pathways. These efforts could lead the way for more personalized cancer prevention and care strategies. DOI - https://doi.org/10.18632/oncotarget.28718 Correspondence to - Khaled J. Zaitoun - kzaitou1@jh.edu Video short - https://www.youtube.com/watch?v=BQFVtreaetI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28718 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, breast cancer, cancer risk factors, blood group antigens, tumor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 10, 2025, titled “Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation.” In this study, first author Masahiko Takahashi and corresponding author Keisuke Okawa led a research team from Kagawa Prefectural Central Hospital and Hyogo Medical University that investigated whether Factor Xa inhibitors (Xa-Is)—a type of blood thinner—can reduce the risk of heart-related complications in patients over 80 with nonvalvular atrial fibrillation (NVAF). The study found that patients using Xa-Is experienced significantly fewer cardiovascular problems than those on other anticoagulants. This finding is especially relevant, as older adults face a high risk of both stroke and heart disease. Atrial fibrillation is a common heart rhythm disorder, particularly in the elderly, that increases the risk of blood clots, heart failure, and stroke. Anticoagulants are often prescribed to prevent clots, but not all types have the same effects on heart health. This study focused on comparing Xa-Is—specifically rivaroxaban, apixaban, and edoxaban—with commonly used drugs such as warfarin and dabigatran. Researchers followed more than 1,000 patients aged 80 and above for up to five years to assess the long-term impact of these medications on cardiovascular outcomes. Patients who used Xa-Is had significantly lower rates of heart failure, artery disease, and cardiovascular death. The risk of cardiovascular problems in the Xa-I group was less than half that of those on non-Xa-I medications. These benefits remained even after adjusting for factors like age, existing heart conditions, and kidney function. Additionally, stroke and all-cause death rates were notably lower in the Xa-I group. “Xa-Is may be useful for not only anticoagulation but also the prevention of cardiovascular events in very old patients with NVAF.” What makes Xa-Is different, according to the researchers, is their ability to inhibit a specific biological pathway—known as Factor Xa–PAR2—that contributes to inflammation, fibrosis, and damage in blood vessels and heart tissue. This effect extends beyond their traditional role in preventing blood clots. Although the study was conducted at a single medical center in Japan, its rigorous design and long follow-up period enhance the reliability of the findings for real-world clinical decision-making. While further studies, especially across multiple centers, are needed to confirm the full range of benefits, this study strongly suggests that Xa-Is may offer broader cardiovascular protection for very old patients. The findings could influence how clinicians choose blood thinners for elderly individuals with atrial fibrillation, potentially improving both survival and quality of life in this growing population. DOI - https://doi.org/10.18632/aging.206238 Corresponding author - Keisuke Okawa - k-ookawa@chp-kagawa.jp Video short - https://www.youtube.com/watch?v=YtbYpfVDVDI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206238 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Factor Xa inhibitor, atrial fibrillation, older patient, cardiovascular events To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 13, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 7, 2025, titled “Pharmacological recapitulation of the lean phenotype induced by the lifespan-extending sulfur amino acid-restricted diet.” In this study, the research team, led by first author Naidu B. Ommi and corresponding author Sailendra N. Nichenametla from the Orentreich Foundation for the Advancement of Science Inc., investigated whether the drug buthionine sulfoximine (BSO) could replicate the effects of sulfur amino acid restriction (SAAR), a challenging diet known to reduce obesity. The study found that BSO produced similar reductions in fat mass and weight gain. This drug-based approach may offer a simpler and safer treatment for obesity, especially for those unable to follow strict dietary plans. Obesity and metabolic disorders raise the risk of chronic illnesses like heart disease, diabetes, and Alzheimer's disease. While SAAR, a diet low in the amino-acids methionine and cysteine, has shown powerful health benefits in animal studies, its translation to humans has been limited by adherence challenges. This new study explored whether BSO, a compound that lowers glutathione (GSH) levels in the body, could mimic SAAR's effects without dietary restriction. Researchers tested four groups of obese mice on high-fat diets. One group received the SAAR diet, another was given a regular diet plus BSO, while two control groups received either no treatment or a supplement that increased GSH levels. The BSO-treated mice showed lower fat mass, reduced liver fat, and prevented weight gain, results comparable to those on the SAAR diet. These benefits occurred without reducing food intake or muscle mass, making BSO a particularly promising treatment option. “BSO mice exhibited all SAAR-induced changes, with two notable differences, i.e., a smaller effect size than that of the SAAR diet and a higher predilection for molecular changes in kidneys than in the liver.” Additional findings revealed that both the SAAR diet and BSO influenced metabolic activity by activating pathways related to fat storage, but they did so in different organs. The SAAR diet had stronger effects in the liver, while BSO acted more in the kidneys. Both interventions increased levels of the amino acid serine, which is associated with lower fat production. Unlike many obesity treatments that suppress appetite or reduce muscle, BSO helped prevent fat accumulation while preserving lean mass and food consumption. No signs of liver or kidney toxicity were observed during the 13-week study, suggesting the drug's safety at the tested dose. Since BSO has previously been evaluated in human clinical trials for other conditions, repurposing it for metabolic diseases may be relatively straightforward. However, the researchers point out that there should be further studies in both animals and humans. If successful, this strategy could provide a practical alternative to difficult-to-maintain diets and help more people manage weight long-term. DOI: https://doi.org/10.18632/aging.206237 Corresponding author: Sailendra N. Nichenametla – snichenametla@orentreich.org Video short - https://www.youtube.com/watch?v=AcCzYTIElGY Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: aging, buthionine sulfoximine, thiols, serine, anti-obesity drugs To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY - May 9, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on May 8, 2025, titled “METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." In this study, researchers Jayasree Peroth Jayaprakash, Pragati Karemore, and Piyush Khandelia from the Birla Institute of Technology and Science, India, discovered that a molecule called METTL3 contributes to the development and spread of oral squamous cell carcinoma (OSCC). The study shows that METTL3 increases the levels of a small RNA molecule called miR-146a-5p, which blocks SMAD4, a key tumor-suppressing gene. These findings help explain why oral cancers are difficult to treat and may offer a new target for more effective therapies. Oral squamous cell carcinoma is a common and aggressive cancer affecting the mouth and throat. It has a high death rate, mainly due to late detection, treatment resistance, and the cancer's ability to invade nearby tissues. In this study, the researchers focused on METTL3, an enzyme that adds chemical tags known as m6A marks to RNA, which change how genetic information is used by cells. They found that METTL3 is unusually active in OSCC cells, causing an increase in miR-146a-5p. This molecule, in turn, blocks the function of SMAD4, which helps control how cells grow and die in our bodies. “METTL3, the primary m6A RNA methyltransferase, is significantly upregulated in OSCC cells leading to increased global m6A levels.” When METTL3 was reduced or chemically blocked, miR-146a-5p levels dropped and SMAD4 levels increased. This shift slowed the growth of cancer cells, increased their death, and made them less likely to spread. When researchers reintroduced miR-146a-5p or lowered SMAD4 levels again, the cancer-promoting behavior returned. These results show that the METTL3–miR-146a-5p–SMAD4 pathway plays a key role in OSCC. The findings open up new possibilities for treatment. Drugs that block METTL3 or miR-146a-5p or that restore SMAD4 could slow or stop tumor growth. One such drug, STM2457, which targets METTL3, has already shown promise in lab studies. As research progresses, targeting this molecular pathway may offer a new strategy in treating OSCC. This discovery improves our understanding of how OSCC develops and avoids the body's defenses. By interfering with this newly discovered pathway, future treatments may become more successful, improving survival rates and quality of life for people with this disease. DOI - https://doi.org/10.18632/oncotarget.28717 Correspondence to - Piyush Khandelia - piyush.khandelia@hyderabad.bits-pilani.ac.in Video short - https://www.youtube.com/watch?v=o5XuDlcIma8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28717 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 7, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 4, 2025, titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.” A research team led by first author Mauricio Moel and corresponding author Stefanie L. Morgan from AgelessRx conducted a clinical trial to determine whether low-dose, intermittent rapamycin could safely improve healthspan in older adults. The findings suggest rapamycin may offer measurable benefits for physical function and overall well-being, reinforcing its potential as a safe intervention to support healthy aging. Aging remains the leading cause of chronic conditions such as heart disease, diabetes, and dementia. While medical advances have extended lifespan, many people still experience declining health and reduced mobility in later years. This growing gap between lifespan and healthspan has driven interest in therapies that target aging itself. Rapamycin, an FDA-approved drug originally used in transplant medicine, has drawn attention for its ability to influence aging-related pathways in animal studies. Until recently, its safety and benefits in healthy human populations were largely unknown. The PEARL trial is the longest study so far to explore rapamycin's use for longevity in healthy aging adults. Researchers followed 114 participants aged 50 to 85 over 48 weeks in a randomized, double-blind, placebo-controlled design. Participants received either a placebo or 5 mg or 10 mg of compounded rapamycin once per week. The study's primary goal was to measure changes in visceral fat, while secondary outcomes included lean muscle mass, blood markers, and quality-of-life assessments. The trial found that low-dose rapamycin was safe and well-tolerated, with serious side effects reported at similar rates across all groups. The most frequent minor issue among rapamycin users was mild gastrointestinal discomfort. While no significant reductions in visceral fat were observed, women taking 10 mg of rapamycin showed significant gains in lean muscle and reported reduced pain. In addition, participants taking 5 mg weekly reported improvements in emotional well-being and general health, as measured by validated surveys. “Our findings provide evidence that these rapamycin regimens are well tolerated with minimal adverse effects when administered for at least one year within normative aging individuals.” Researchers noted some limitations, including the relatively small and health-conscious participant group, which may have limited the ability to detect larger effects. The compounded form of rapamycin used also had lower absorption than commercial versions, possibly reducing its impact. Overall, the PEARL trial provides early clinical evidence that low-dose rapamycin may help support physical and emotional well-being in older adults. Further studies with larger and more diverse populations will be essential to confirm the study results and refine dosing strategies for broader application. DOI: https://doi.org/10.18632/aging.206235 Corresponding author: Stefanie L. Morgan – stefanie@agelessrx.com Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: rapamycin, aging, healthspan, longevity, geroscience To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — May 6, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 2, 2025, titled “Fisetin ameliorates vascular smooth muscle cell calcification via DUSP1-dependent p38 MAPK inhibition.” In this study, researchers at Johannes Kepler University Linz found that fisetin, a natural substance found in fruits and vegetables, helps protect blood vessels from hardening, which is a common problem in older adults and people with kidney disease. This discovery highlights fisetin's potential to prevent vascular calcification and reduce cardiovascular damage caused by aging and chronic kidney disease. The research, led by first author Mehdi Razazian and corresponding author Ioana Alesutan, focused on vascular calcification—a condition in which blood vessels stiffen due to calcium deposits. This process is common in aging and chronic kidney disease and increases the risk of heart attacks and strokes. Using human and mouse study models, the researchers tested fisetin's ability to prevent this calcification in vascular smooth muscle cells (VSMC), which play a key role in maintaining vessel health. Fisetin, known for its anti-inflammatory and antioxidant properties, significantly reduced calcium buildup and calcification markers under stress conditions that mimic disease. The team also discovered that fisetin suppresses activity in a signaling pathway called p38 MAPK, which is known to promote calcification. This effect depends on a protein called DUSP1. When DUSP1 was blocked, fisetin could no longer protect the cells, showing that this protein is essential for its anti-calcification activity. The researchers confirmed fisetin's protective effects in isolated mouse arteries and in living mice treated with high doses of vitamin D, which typically increases arterial calcification. “Mechanistically, fisetin requires the phosphatase DUSP1 to inhibit p38 MAPK in order to mediate its protective effect on VSMC calcification.” Importantly, the researchers tested fisetin under conditions similar to human disease. When VSMCs were exposed to blood serum from kidney dialysis patients—a condition known to trigger vascular calcification—fisetin again reduced calcium buildup and protected the cells. These findings suggest fisetin could be useful in countering the harmful vascular effects seen in chronic kidney disease. This study adds to growing evidence that fisetin may protect blood vessels from aging-related damage. While more research is needed before it can be used in clinical treatments, the study highlights fisetin as a promising candidate for slowing or preventing vascular calcification. The findings could have broad implications for aging populations and individuals with kidney disease, who are at greater risk for heart problems due to vascular stiffening. Read the full paper: DOI: https://doi.org/10.18632/aging.206233 Corresponding author: Ioana Alesutan – ioana.alesutan@jku.at Keywords: aging, vascular calcification, vascular smooth muscle cells, fisetin, dual-specificity phosphatase 1, p38 MAPK ______ To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY - May 5, 2025 – Oncotarget, #published by Impact Journals, is proud to #announce its presence as an #exhibitor at the 47th Annual Meeting of the Society for Scholarly Publishing (SSP), taking place May 28–30, 2025, at the Hilton Baltimore in Maryland. Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on cancer and aging research. Attendees are invited to stop by Booth #209 to meet members of the Oncotarget team and learn more about the journal's latest initiatives. This year's conference theme, “Reimagining the Future of Scholarly Publishing at the Intersection of Value and Values,” highlights critical topics such as artificial intelligence, research ethics, and transparency in science—principles that closely align with Oncotarget's commitment to rigorous peer review and scientific integrity. We look forward to connecting with SSP attendees to discuss Oncotarget's mission, explore potential collaborations, and emphasize the role of open science in advancing cancer research and related fields. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media at: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – May 5, 2025 – Aging (Aging-US), #published by Impact Journals, is pleased to #announce its participation at the upcoming Society for Scholarly Publishing (SSP) 47th Annual Meeting. The #event will take place from May 28-30, 2025, in Baltimore, Maryland. Attendees are invited to visit Booth No. 209 to meet members of the Aging (Aging-US) team. The 2025 meeting theme, “Reimagining the Future of Scholarly Publishing at the Intersection of Value and Values,” underscores the urgency of adapting to rapid technological change, including AI, and addressing growing concerns around research integrity and trust. These priorities align closely with our mission to foster open, reliable, and impactful scientific communication in the field of aging and age-related diseases. In addition, the Longevity & Aging Series - hosted by Dr. Evgeniy Galimov and presented by Aging (Aging-US) - is a Finalist for a Society for Scholarly Publishing (SSP) 2025 EPIC Award in the Video/Film category. Winners will be announced at the EPIC Awards Celebration on May 29. We look forward to connecting with SSP 2025 attendees to share more about Aging (Aging-US) and our publishing initiatives. To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
⭐️Leave a Rating + Review
BUFFALO, NY — May 1, 2025 — A new #research paper was #published in Aging (Aging-US) on April 2, 2025, as the #cover of Volume 17, Issue 4, titled “Decreased mitochondrial NAD+ in WRN deficient cells links to dysfunctional proliferation.” In this study, the team led by first author Sofie Lautrup and corresponding author Evandro F. Fang, from the University of Oslo and Akershus University Hospital in Norway, discovered that cells from people with Werner syndrome (WS)—a rare genetic disorder that causes premature aging—have low levels of a molecule called NAD+ in their mitochondria. This molecule is essential for energy production, cellular metabolism, and maintaining cell health. The researchers also found a potential way to improve cell function in WS patients, pointing to new directions for treating age-related decline and other premature aging disorders. Werner syndrome leads to signs of aging much earlier than normal, including problems such as cataracts, hair loss, and atherosclerosis by age 20 to 30. The team found that when the WRN gene is missing or damaged, cells cannot maintain healthy NAD+ levels in their mitochondria. As a result, the cells age more quickly and stop growing properly. When the researchers boosted NAD+ levels using nicotinamide riboside (a vitamin B3 compound) the affected stem cells and skin cells from patients showed less aging and improved mitochondrial activity. “Interestingly, only 24 h treatment with 1 mM nicotinamide riboside (NR), an NAD+ precursor, rescued multiple pathways in the WRN−/− cells, including increased expression of genes driving mitochondrial and metabolism-related pathways, as well as proliferation-related pathways.” The study also found that the WRN gene helps regulate other important genes that control how NAD+ is made in the body. Without WRN, this system becomes unbalanced, which affects how cells function, grow, and respond to stress. Although adding more NAD+ helped some cells look healthier, it could not completely fix the growth problems in other types of lab-grown cells. This suggests that while NAD+ supplementation is beneficial, it cannot fully replace the essential functions of the WRN gene. These findings offer new insights into the biological mechanisms of aging and reinforce the therapeutic potential of targeting NAD+ metabolism in age-related and genetic diseases. Future studies will aim to better understand how subcellular NAD+ regulation interacts with mutations like those seen in WS. Finally, this research supports ongoing efforts to develop NAD+-based treatments that could slow cellular aging and improve quality of life for patients with premature aging conditions. DOI - https://doi.org/10.18632/aging.206236 Corresponding author - Evandro F. Fang - e.f.fang@medisin.uio.no Video short - https://www.youtube.com/watch?v=WpRpi8TYPfU Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206236 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Werner syndrome, premature aging, NAD+, mitochondria, proliferation To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
⭐️Leave a Rating + Review
From Spotlights to Stumbles: Tales of Dance & TheaterGuest: Bob Spiotto Host: Anna Harsh, M.A (Communication) B.A (Dance), E-RYT200 Yoga, Pilates certified. Over 32 years of teaching experience with performances around the world. Have you had performances that were nothing but stumbles on stages? My next guest has worked in the entertainment industry for over 40 years with acting, directing and producing is going to offer advice.Bob Spiotto holds a B.F.A. in Theater Performance - Hofstra University, and a M.F.A. in Directing - The Catholic University of America (Washington,D.C.) Bob has directed hundreds of theater productions at various regional and professional theaters, schools and universities, as well as for various organizations and companies, and while at Hofstra, he also co–founded the LittleTop Theater Company, and was an advisor to several on campus student theatrical organizations. He has also served as a host, master of ceremonies, writer andauctioneer for many high profile private and public events, as well as benefits.Follow Bob on Facebook: @BobSpiotto https://www.facebook.com/bob.spiotto/Anna's Websites: www.AnnaHarsh.com Tarantella Workshop in NY May 4, 2pm- 4pm Long Island City School of Ballet, Long Island City NYwww.AllegroDanceCompany.net #THESHOWMUSTGOON #Showbiz #Performance #Dance #Theater #WomenSpeakers #Podcasting #TheDanceFloorPodcast #AnnaHarshDancer #AllegroDanceCompany #NY
⭐️Leave a Rating + Review
⭐️Leave a Rating + Review
⭐️Leave a Rating + Review
⭐️Leave a Rating + Review
⭐️Leave a Rating + Review
⭐️Leave a Rating + Review
Leo Terrell, Fox News Contributor and Civil Rights Attorney, is here to break down Trump's trial against the left wing establishment of NY and the complete anarchy happening on campuses with ZERO regard for authority. See omnystudio.com/listener for privacy information.
Mike Sarraille is the founder and CEO of Talent War Group, Legacy Expeditions, ATTA, and head of the Men's Journal Everyday Warrior Nation. Mike is a two-time best-selling author, globally ranked leadership speaker, documentary filmmaker, entrepreneur, and extreme adventurer. He is a former Recon Marine and Scout-Sniper, and retired US Navy SEAL officer with 20 years of experience in Special Operations, including the elite Joint Special Operations Command. What you'll learn on this episode: Leadership lessons from Navy SEAL training principles The importance of mental toughness and discretionary thinking The importance of discomfort for character development and overall growth How accountability in teamwork drives individual growth and collective excellence How shared hardship and adversity can help to build trust and strong relationships The impact of prioritizing preparation over execution to build resilience and readiness Dive into Triple 7 and how it honors the legacy of service and sacrifice of U.S. and Allied troops Additional Resources: About Mike: www.mikesarraille.com Linkedin: michaelsarraille IG: @mr.sarraille Twitter: @mjsarraille Facebook: Mike Sarraille Get Mike's Books: The Everyday Warrior The Talent War About Triple 7: www.legacyexpeditions.com Click here to watch Triple 7 Trailer Click here to purchase tickets! TRIPLE 7 PREMIER SCHEDULE: May 11: New York City, NY May 13: Tampa, FL May 14: Austin, TX May 15: Dallas, TX May 16: Los Angeles, CA
#SistersInLaw On Tour: Go to politicon.com/tour to get ready for our live tour in May! We're starting off in Portland, OR– May 12. New York City, NY– May 19. Washington, DC– May 21. Get your tickets today - politicon.com/tour #SistersInLaw discuss the latest news coming from the Manhattan DA regarding the Stormy Daniels related case that might get Donald indicted. Then, they look at recent developments in the special council's classified documents investigation against him, and the significance of his choice of Waco, TX for his upcoming rally and the events that made that city a touchstone of the alt-right. WEBSITE & TRANSCRIPT From Joyce Email: SISTERSINLAW@POLITICON.COM or tweet using #SistersInLaw Please Support This Week's Sponsors HelloFresh: Enjoy 60% off plus free shipping on delicious HelloFresh meals delivered right to your door when you go to hellofresh.com/sisters60 and use promo code: SISTERS60 Athena Club: Go to athenaclub.com and use promo code: SIL today and you'll get 25% off your first order! Reel Paper: Get 30% off your first order and free shipping on bamboo based environmentally friendly paper products by going to reelpaper.com/sisters and signing up for a subscription using promo code: SISTERS. Lomi: Turn your food waste into dirt with the press of a button with Lomi. Use the code SIL to save $50 at lomi.com/SIL Kitsch: Update your style with 30% off your order when you go to mykitsch.com/sisters Get More From #Sisters In Law Joyce Vance: Twitter | University of Alabama Law | MSNBC | Civil Discourse Substack Jill Wine-Banks: Twitter | Facebook | Website | Author of The Watergate Girl: My Fight For Truth & Justice Against A Criminal President Kimberly Atkins Stohr: Twitter | Boston Globe | WBUR | Unbound Newsletter Barb McQuade: Twitter | University of Michigan Law | Just Security | MSNBC
#SistersInLaw On Tour: Go to politicon.com/tour for tickets Live tour in May Portland, OR– May 12. New York City, NY– May 19. Washington, DC– May 21. Get your tickets today - politicon.com/tour #SistersInLaw discuss the threat to women's rights coming from big corporations like Walgreen's and our power as consumers to boycott and make our voices heard. Then, they break down the multiple possibilities for indictment facing Donald in the states and from the federal government, before examining the perils of Tucker being able to control the J6 narrative at Fox. WEBSITE & TRANSCRIPT Email: SISTERSINLAW@POLITICON.COM or tweet using #SistersInLaw Please Support This Week's Sponsors HelloFresh: Enjoy 60% off plus free shipping on delicious HelloFresh meals delivered right to your door when you go to hellofresh.com/sisters60 and use promo code: SISTERS60 Blueland: For 15% off your first order of green cleaning products, go to blueland.com/sisters Noom: Sign up for a trial of effective weight loss solutions with Noom and check out their groundbreaking book on health when you go to noom.com/sistersinlaw Athena Club: Go to athenaclub.com and use promo code: SIL today and you'll get 25% off your first order! Get More From #Sisters In Law Joyce Vance: Twitter | University of Alabama Law | MSNBC | Civil Discourse Substack Jill Wine-Banks: Twitter | Facebook | Website | Author of The Watergate Girl: My Fight For Truth & Justice Against A Criminal President Kimberly Atkins Stohr: Twitter | Boston Globe | WBUR | Unbound Newsletter Barb McQuade: Twitter | University of Michigan Law | Just Security | MSNBC
#SistersInLaw On Tour: Go to politicon.com/tour to get ready for our live tour in May! We're starting off in Portland, OR– May 12. New York City, NY– May 19. Washington, DC– May 21. Get your tickets today - politicon.com/tour #SistersInLaw lay out the ramifications of the Dominion lawsuit against Fox News and what it means for the future of their analysis and reporting, before covering the latest developments in the abortion war– including how Walgreens has shied away from protecting women's access to the pill, and the possible legal remedies. Then, they examine policing practices in the wake of events in Louisville. WEBSITE & TRANSCRIPT Email: SISTERSINLAW@POLITICON.COM or tweet using #SistersInLaw From #SistersInLaw From Jill NY Times article about “Birthright” You can watch “Birthright” on PlutoTV From Kim On the latest in the abortion wars From Barb On recent J6 developments Please Support This Week's Sponsors HelloFresh: Enjoy 65% off plus free shipping on delicious HelloFresh meals delivered right to your door when you go to hellofresh.com/sisters65 and use promo code: SISTERS65 Olive & June: Get 20% off your mani system when you go to oliveandjune.com/sil and use promo code: SIL OSEA Malibu: Get 10% off your order of clean beauty products from OSEA along with free samples and free shipping on orders over $60 when you go to oseamalibu.com and use promo code: SISTERS Honey: To get Honey for free and start saving on your shopping, go to joinhoney.com Helix: Helix is offering up to 20% off all mattress orders and two free pillows for our listeners! go to helixsleep.com/sisters. Get More From #Sisters In Law Joyce Vance: Twitter | University of Alabama Law | MSNBC | Civil Discourse Substack Jill Wine-Banks: Twitter | Facebook | Website | Author of The Watergate Girl: My Fight For Truth & Justice Against A Criminal President Kimberly Atkins Stohr: Twitter | Boston Globe | WBUR | Unbound Newsletter Barb McQuade: Twitter | University of Michigan Law | Just Security | MSNBC
#SistersInLaw On Tour: Go to politicon.com/tour to get ready for our live tour in May! We're starting off in Portland, OR– May 12. New York City, NY– May 19. Washington, DC– May 21. Get your tickets today - politicon.com/tour #SistersInLaw explain the two cases before the SCOTUS seeking to undermine President Biden's student loan relief and how they might be decided. They also discuss the DOJ's consideration of civil suits targeting Trump's actions that resulted in injuries during the J6 insurrection, before taking on Governor DeSantis' authoritarian war on Disney and the 1st Amendment. WEBSITE & TRANSCRIPT Email: SISTERSINLAW@POLITICON.COM or tweet using #SistersInLaw From #SistersInLaw From Kim On SCOTUS Chief Justice Roberts' Most Recent Actions Please Support This Week's Sponsors HelloFresh: Enjoy 65% off plus free shipping on delicious HelloFresh meals delivered right to your door when you go to hellofresh.com/sisters65 and use promo code: SISTERS65 Kitsch: Update your style with 30% off your order when you go to mykitsch.com/sisters Thrive Causemetics: For 15% off incredible clean and cause focused beauty products, go to thrivecausemetics.com/sisters and use promo code: QE2FY5D28CB2 Moink: For farm fresh meats and 1 year of free filet mignon, go to moinkbox.com/sisters Pair Eyewear: Experiment with who you can be in 2023 with amazing new eyewear and get 15% off when you go to paireyewear.com/sisters. Get More From #Sisters In Law Joyce Vance: Twitter | University of Alabama Law | MSNBC | Civil Discourse Substack Jill Wine-Banks: Twitter | Facebook | Website | Author of The Watergate Girl: My Fight For Truth & Justice Against A Criminal President Kimberly Atkins Stohr: Twitter | Boston Globe | WBUR | Unbound Newsletter Barb McQuade: Twitter | University of Michigan Law | Just Security | MSNBC
#SistersInLaw On Tour: Go to politicon.com/tour to get ready for our live tour in May! We're starting off in Portland, OR– May 12. New York City, NY– May 19. Washington, DC– May 21. Get your tickets today - politicon.com/tour #SistersInLaw break down the latest subpoenas and investigation developments involving Trump– including the targeting of Jared and Ivanka and the grand juror's ill-advised media tour. Then, they look at the lies of Mark Brnovich relating to important 2020 election information, before discussing Section 230 of the Communications Decency Act and anti-terrorism law. WEBSITE & TRANSCRIPT Email: SISTERSINLAW@POLITICON.COM or tweet using #SistersInLaw From #SistersInLaw From Barb On grand juror Emily Kors going on a media tour Please Support This Week's Sponsors Reel Paper: Get 30% off your first order and free shipping on bamboo based environmentally friendly paper products by going to reelpaper.com/sisters and signing up for a subscription using promo code: SISTERS. Calm: Perfect your meditation practice and get better sleep with a 40% off a premium subscription when you go to calm.com/sisters Noom: Sign up for a trial of effective weight loss solutions with Noom and check out their groundbreaking book on health when you go to noom.com/sistersinlaw HelloFresh: Enjoy 65% off plus free shipping on delicious HelloFresh meals delivered right to your door when you go to hellofresh.com/sisters65 and use promo code: SISTERS65 Get More From #Sisters In Law Joyce Vance: Twitter | University of Alabama Law | MSNBC | Civil Discourse Substack Jill Wine-Banks: Twitter | Facebook | Website | Author of The Watergate Girl: My Fight For Truth & Justice Against A Criminal President Kimberly Atkins Stohr: Twitter | Boston Globe | WBUR | Unbound Newsletter Barb McQuade: Twitter | University of Michigan Law | Just Security | MSNBC
© 2020-2026 Ivy Podcast Discovery LLC
